Navigation Links
Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure
Date:10/1/2009

SAN MATEO' Calif.' Oct. 1 /PRNewswire/ -- Corthera Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to relaxin, the company's investigational drug for the treatment of acute heart failure (AHF). The Fast Track program facilitates the development and expedites the review of new drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

"Fast Track designation for the relaxin heart failure program is an important acknowledgement by the FDA of the need for advancements in the treatment of AHF," said Stan Abel, CEO of Corthera. "We are excited to be launching Phase 3 given our goal of advancing the development of relaxin as rapidly as possible for the benefit of patients who are in need of new treatment options."

Corthera's completed Pre-RELAX-AHF study is the Phase 2 portion of a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, international trial designed to evaluate the efficacy and safety of relaxin for the treatment of AHF. In Pre-RELAX-AHF, the objective was proof-of-concept and dose and endpoint selection. Data from the Phase 2 study were presented at the American College of Cardiology conference earlier this year and published in the medical journal, The Lancet. These data from 234 patients in eight countries showed that when administered with standard-of-care therapy for AHF, patients receiving relaxin had greater and longer-lasting relief of dyspnea (shortness of breath). Relaxin treatment was associated with consistent trends in improvement of the hospital course of patients, prevention of heart failure worsening during hospitalization, shortening of in hospital stay and improved longer-term outcomes following discharge when compared to placebo. Corthera is currently initiating enrollment in the Phase 3 RELAX-AHF study, the objective of which is to confirm the promising safety and efficacy of relaxin seen in these patients. The Pre-RELAX-AHF / RELAX-AHF study was designed and conducted in collaboration with Momentum Research, headed by Dr. Gad Cotter, a noted heart failure expert.

"Patients with acute heart failure remain a major clinical challenge with very high morbidity and mortality rates and limited treatment options," said John R. Teerlink, M.D., Professor of Medicine, University of California San Francisco, Director of Heart Failure, Veterans Affairs Medical Center, San Francisco, and co-principal investigator of the studies. "The importance of this Fast Track designation is two-fold as it acknowledges a significant unmet medical need and recognizes relaxin's potential as an important treatment option for patients with AHF."

According to U.S. data, there are more than 3 million hospital discharges each year with heart failure as a diagnosis, with significant short-term rehospitalization and one-year mortality rates. It is the single largest expense to Medicare, accounting for more than $13 billion in hospitalization costs. The great majority of acute heart failure patients have fluid accumulation in the lungs (congestion) that causes shortness of breath (dyspnea) and other complications. For these patients, the current standard of care includes diuretics and vasodilators. Available agents from both of these classes of agents have been associated with renal impairment, hypotension and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-pregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Corthera's lead product candidate, relaxin, is currently being evaluated in clinical trials for the treatment of acute heart failure. The company has worldwide rights to develop and commercialize relaxin. For more information, visit www.corthera.com.

    Contact:   Andreas Marathovouniotis or David Schull
               Russo Partners
               (212) 845-4235
               (212) 845-4271
               andreas.marathis@russopartnersllc.com
               david.schull@russopartnersllc.com

SOURCE Corthera Inc.


'/>"/>
SOURCE Corthera Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
2. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
3. Results From Study Show Promising Efficacy and Safety Results for Cortheras Relaxin in Acute Heart Failure
4. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
5. Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
6. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
7. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
8. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
9. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
10. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
11. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):